Ac-Asp-Glu . H2O 品牌：Peptide

发表于2025年5月17日由Whatman官网

Ac-Asp-Glu . H2O

品牌：Peptide
CAS No.：3106-85-2
储存条件：-20℃
纯度：–

产品编号 (生产商编号)	等级	规格	运输包装	零售价(RMB)	库存情况	参考值
338-41671	–	100mg	–	咨询	–	–

* 干冰运输、大包装及大批量的产品需酌情添加运输费用

* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动，恕不另行通知，确切详情请联系上海金畔生物科技有限公司。

Z-Tyr-Glu 品牌：Peptide

发表于2025年4月25日由Whatman官网

Z-Tyr-Glu

品牌：Peptide
CAS No.：988-70-5
储存条件：2-10℃
纯度：–

产品编号 (生产商编号)	等级	规格	运输包装	零售价(RMB)	库存情况	参考值
335-30691	–	0.1g	–	咨询	–	–

* 干冰运输、大包装及大批量的产品需酌情添加运输费用

Arg-Gly-Glu-Ser

发表于2025年3月31日由Whatman官网

Arg-Gly-Glu-Ser;

Arg-Gly-Glu-Ser 是一种与 RGD 有关的多肽，控制 RGDS 对纤维蛋白原与激活的血小板结合的抑制活动。

Arg-Gly-Glu-Ser Chemical Structure

CAS No. : 93674-97-6

规格		是否有货
100 mg	;	询价	;
250 mg	;	询价	;
500 mg	;	询价	;

* Please select Quantity before adding items.

Arg-Gly-Glu-Ser 的其他形式现货产品:

Arg-Gly-Glu-Ser TFA

生物活性

Arg-Gly-Glu-Ser is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.

体内研究
(In Vivo)

Arg-Gly-Glu-Ser (5 mg/kg) in combination with LPS or saline + RGDS does not affect neutrophil and macrophage cell numbers and has no effect on protein accumulation compared with LPS- or saline-treated mice, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

447.44

Formula

C₁₆H₂₉N₇O₈

CAS 号

93674-97-6

Sequence

Arg-Gly-Glu-Ser

Sequence Shortening

RGES

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

溶解性数据

In Vitro:;

H₂O : 2 mg/mL (4.47 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2349 mL	11.1747 mL	22.3494 mL
5 mM	—	—	—
10 mM	—	—	—

参考文献

[1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.

Animal Administration ^[1]	Mice^[1] Mouse pharyngeal aspiration is performed in the assay. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with RGDS or Arg-Gly-Glu-Ser peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered RGDS or Arg-Gly-Glu-Ser peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.

Animal Administration
^[1]

Mice^[1]
Mouse pharyngeal aspiration is performed in the assay. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with RGDS or Arg-Gly-Glu-Ser peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered RGDS or Arg-Gly-Glu-Ser peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.